Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Shares Outstanding (Weighted Average) (2020 - 2022)

Atea Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $83.2 million for Q3 2022.

  • Quarterly results put Shares Outstanding (Weighted Average) at $83.2 million for Q3 2022, up 0.5% from a year ago — trailing twelve months through Sep 2022 was $83.2 million (up 0.5% YoY), and the annual figure for FY2021 was $82.8 million, up 283.56%.
  • Shares Outstanding (Weighted Average) for Q3 2022 was $83.2 million at Atea Pharmaceuticals, roughly flat from $83.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for AVIR hit a ceiling of $83.3 million in Q2 2022 and a floor of $10.1 million in Q1 2020.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $82.7 million (2021), compared with a mean of $57.5 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 720.03% in 2021 and later increased 0.5% in 2022.
  • Atea Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $21.6 million in 2020, then soared by 283.56% to $82.8 million in 2021, then increased by 0.5% to $83.2 million in 2022.
  • The last three reported values for Shares Outstanding (Weighted Average) were $83.2 million (Q3 2022), $83.3 million (Q2 2022), and $83.2 million (Q1 2022) per Business Quant data.